Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell?

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX)’s stock price traded down 4.9% on Wednesday . The stock traded as low as $0.1926 and last traded at $0.2007. 2,809,196 shares were traded during trading, a decline of 74% from the average session volume of 10,784,255 shares. The stock had previously closed at $0.2110.

Theriva Biologics Stock Down 4.9%

The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $6.77 million, a PE ratio of -0.01 and a beta of 0.34. The business’s 50-day moving average price is $0.23 and its 200-day moving average price is $0.35.

Theriva Biologics (NYSEAMERICAN:TOVX) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.45) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Theriva Biologics stock. Two Sigma Investments LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned about 0.64% of Theriva Biologics at the end of the most recent reporting period. 6.17% of the stock is owned by institutional investors.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.